U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
Go back to U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition
November 19, 2021 9:33 AM EST
Longeveron (NASDAQ: LGVN) Halted on LUDP, Up 90%
...
More
November 19, 2021 7:47 AM EST
Longeveron (NASDAQ: LGVN) Extends Gain, Up 100%
...
More
November 18, 2021 10:16 AM EST
Longeveron (NASDAQ: LGVN) Halted on LUDP, Up 118%
...
More
